



Press release

STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey

- Total carbon emissions by STADA reduced by 25% between 2020 and 2023
- Around 45% of STADA's electricity consumption now comes from renewable sources, as detailed in newly-published STADA Sustainability Report 2023
- STADA CEO Peter Goldschmidt: "Our sustained progress has positioned STADA among the top 6% of the most sustainable pharmaceutical companies globally."

Bad Vilbel, Germany – 21 May 2024 – STADA continues its sustainability journey by reducing its total carbon emissions by almost 25% between 2020 and 2023. This milestone in achieving the group's carbon-reduction commitment of cutting absolute Scope 1 and 2 carbon emissions by 42% between 2020 and 2030, in line with the Paris Agreement, is just one of many steps on STADA's journey detailed in the just-published STADA Sustainability Report 2023.

"Our sustained progress has positioned STADA among the top 6% of the most sustainable pharmaceutical companies globally. This reflects our commitment to working as a trusted partner with customers, regulators, and capital market stakeholders, establishing a solid foundation for sustained success," states STADA CEO Peter Goldschmidt.

Over recent months, the Group continued to develop green energy strategies, such that around 45% of STADA's electricity consumption now comes from renewable sources. Such initiatives contributed to independent agency Sustainalytics ranking STADA among the top



6% of all companies within its Pharmaceuticals sector comprising almost 900 companies appraised in terms of ESG or sustainability risk¹, and top 2% among our direct peers.

The foundation of STADA's ability to fulfil its purpose of Caring for People's Health as a Trusted Partner is its sustainable, reliable and competitive medicines supply chain and manufacturing network. This underpins STADA's efforts to improve access to medicines, not least through having launched around 880 products and obtained more than 2,500 regulatory approvals for over 200 active ingredients and combinations in more than 60 countries during 2023.

Germany-based STADA continues to invest in its European supply-chain network, not least in a new packaging and logistics hub, with an annual capacity of around 100 million packs per year, that the company is currently establishing in Turda, Romania. The first solid-dose medicines from this site, in which STADA has invested more than €50 million, will be shipped to customers later this year, thereby strengthening security of medicines supply in Europe.

Beyond environmental initiatives, STADA Sustainability Report 2023 provides numerous local examples and case studies of the Group's commitment to improvements in line with UN Sustainable Development Goals. For example, in Germany, an ongoing collaboration with the Red Cross – through which money is donated for each pack of STADA non-prescription or OTC generics sold through pharmacies – has in the past one-and-a-half years raised €250,000 for good causes. Read further details [here](#).

¹ [STADA Arzneimittel AG ESG Risk Rating \(sustainalytics.com\)](https://www.sustainalytics.com)

Copyright ©2022 Sustainalytics. All rights reserved.

This press release contains information developed by Sustainalytics (www.sustainalytics.com). Such information and data are proprietary of Sustainalytics and/or its third party suppliers (Third Party Data) and are provided for informational purposes only. They do not constitute an endorsement of any product or project, nor an investment advice and are not warranted to be complete, timely, accurate or suitable for a particular purpose. Their use is subject to conditions available at www.sustainalytics.com/legal-disclaimers.

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler

Chairman of the Supervisory Board: Dr. Günter von Au



About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 115 countries. In financial year 2023, STADA achieved group sales of EUR 3,735 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 802 million. As of 31 December 2023, STADA employed 11,667 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18

61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Follow [@STADAGroup](#) on LinkedIn

Additional information for capital market participants:

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18

61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au